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1) How and when did your company start, and where are you
located?
TILT Biotherapeutics Ltd. was founded in 2013 by Akseli
Hemminki (MD, PhD, CEO) based on his team’s important
patient observations and findings in the lab. The company is
based in Helsinki, Finland.
2) How many employees do you have, and how do you find and
attract them?
TILT has a team of 7 permanent employees and 2 PhD stu-
dents. Some of the ways to attract the team include interesting
work, autonomy, and employee options. The ability to help
patients with cancer is a powerful motivating factor for many
individuals.
3) What are the main focus and platform technology(ies) of
your company?
Solid tumors, for which TILT is developing treatments con-
stitute over 90% of all cancers. Current treatments of metastatic
disease lack curative potential and limited treatment options
are available. TILT technology can be used in most types of
metastatic solid tumors and thus there are thousands of patient
candidates for therapy annually.
The company’s patented technology involves utilization of
oncolytic viruses for enhancement of tumor T-cell therapy. Ini-
tial embodiments of the technology will be used to enable
tumor infiltrating lymphocyte (TIL), chimeric antigen receptor
(CAR-T) and checkpoint inhibiting antibody therapy of solid
tumors.
4) Can you provide a short overview of your product pipeline?
The products of TILT are armed oncolytic adenoviruses
modified in various ways, to allow their use for enhancing T-
cell therapy. The lead candidate is a preclinical stage TNFa/IL2
armed oncolytic adenovirus (TILT-123). Curative preclinical
efficacy results have been published and the virus backbone has
been previously demonstrated safe in humans. GMP produc-
tion is ongoing and the first phase I clinical trial is aimed to
start early 2018. The first trial will take place in Europe and
address metastatic melanoma in patients receiving TILs and
TILT-123. Additional trials in other solid tumor indications are
planned in combination with TILT-123 and a checkpoint mod-
ulator or a CAR-T product.
In addition to TILT-123, the company has other patent-pro-
tected products in the pipeline, including oncolytic viruses cod-
ing for bispecific antibodies.
5) Who is your competition, and what advantage(s) do your
products / technology offer?
TILT’s competitors include companies like Psioxus, Lokon
Pharma, Viralytics, Transgene, and Amgen (T-VEC).
TILT-123 is innovative in many aspects as compared with
the competition. It is the only oncolytic virus designed with T-
cells in mind, and this design is based on patient observations,
not just laboratory data. TILT-123 is armed with the most
potent cytokines in the context of adaptive anti-tumor
responses, it is genetically modified for improved access to can-
cer cells and for improved safety. Moreover, adenovirus is the
most immunogenic virus type and possible to upscale in
manufacturing for industrial production. Importantly, TILT’s
virus backbone has already been demonstrated safe in human
and is able to access distant tumors by vascular route. There-
fore, in addition to intratumoral administration, the product
can be administered by systemic route.
6) What were the “highlights“ in your recent product
development?
Recent highlights include publication of curative preclinical
efficacy with TILT-123 as well as proof of concept with CAR-T
and anti-PD-1 therapy. TILT also successfully completed Scien-
tific Advice with EMA and obtained an Advance Therapy
Medicinal Product Classification for TILT-123. The company
is now advancing with local regulatory authorities to obtain
clinical trial authorizations for its first-in-human clinical trial.
A new funding round was closed last year, which allows TILT
to complete one Phase I trial. The company has raised almost
10M€.
7) What have been the most critical problems in developing
products in your field, and how can your company’s tech-
nology help overcome these problems?
Adoptive T-cell therapy of humans has yielded promising
results in TIL therapy of metastatic melanoma, but it is
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associated with severe side effects due to pre-conditioning che-
motherapy and post-conditioning IL-2. TILT-123 is the only
virus designed specifically for T-cell stimulation with IL2 and
TNFa arming. Improved safety with TIL therapy is reached
when used together with TILT’s product as pre-conditioning
chemo and post-conditioning IL-2 can be left out.
With CAR-T excellent results have been obtained in
CD19C leukemia, but not in solid tumors. With mesothelin
C CAR-T therapy, better efficacy in solid tumors has been
demonstrated in preclinical setting when administered with
TILT-123.
Checkpoint inhibitors have been approved and work in
many tumor types, but only 10–50% of patients are benefiting.
Adenoviruses are the perfect enabler of checkpoint inhibition
in cold and excluded tumors, to greatly extend the population
of patients benefiting.
8) What is your company’s value proposition?
TILT is the world leading company developing oncolytic
immunotherapies for enabling T-cell therapy of solid tumors.
The patented technology will be available for licensing and can
be a valuable asset for the immuno-oncology pipeline of a big
pharma. Vision of TILT’s founder is to cure solid tumors with
TILT technology.
9) What business development strategy do you pursue?
Objective is to establish collaborations with international
venture capitalists or other funding organizations to fund addi-
tional phase I work. Moreover, TILT aims to fund later devel-
opment with upfront and milestone payments from potential
licensing and/or co-development deal(s) with pharma. Compa-
nies having synergic technologies in the immuno-oncology
field, notably those with checkpoint inhibitors or CAR-T are
interesting potential future partners.
10) How does your company attract partners?
By scientific excellence, IP protection, and efficient early
development work. Partners are attracted by communication
and press releases on major development advancements, publi-
cations of scientific results in peer-reviewed journals, poster
presentations in scientific congresses, and by participation to
the main business development events.
11) Who are your most important partners?
TILT’s important financial supporters are Tekes, Lifeline
Ventures, angel investors, and European Comission. In terms
of science, TILT is collaborating with world’s leading research
groups: University of Helsinki – CGTG, University of Pennsyl-
vania - Carl June’s group, and Heidelberg – DKFZ. Process
development work is supported by Merck group.
12) How do you balance performing work in-house vs out-
sourcing?
TILT has enough internal resources to manage all the main
functions: preclinical and clinical research, regulatory and
GMP production, and business. Out-sourcing of tasks like GLP
studies, GMP production, and clinical operations allows the
use of external expertise with low fixed costs. Collaboration
with Akseli Hemminki’s research group at University of
Helsinki allows TILT to generate new preclinical data and in
return gives the research a translational aspect.
13) What are your product development goals for the next 3
years?
In 3 years from now, TILT’s objective is to have generated
clinical data of dozens of patients from at least two Phase I tri-
als and to have helped some cancer patients to live longer. Initi-
ation of first-in-man trials with TILT’s lead product (TILT-123)
is planned for next year. One of the trials will take place in
France and Denmark and address metastatic melanoma with
TIL-treatment. An additional trial, with anti-PD1 treatment in
melanoma is planned in the US. GMP production of the clinical
material is currently ongoing. In the future, TILT is also inter-
ested in initiating clinical trials in other solid tumor indications
and with other T-cell therapies, notably with CAR-T.
For more information visit http://tiltbio.com/
HUMAN VACCINES & IMMUNOTHERAPEUTICS 971
